Influence of Medication on Functional Connectivity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03612713|
Recruitment Status : Recruiting
First Posted : August 2, 2018
Last Update Posted : November 2, 2018
|Condition or disease||Intervention/treatment||Phase|
|Prescription Drug Abuse (Not Dependent)||Drug: Oxycodone Medication First Drug: Placebo First||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Influence of Medication on Functional Connectivity|
|Actual Study Start Date :||October 30, 2018|
|Estimated Primary Completion Date :||September 2020|
|Estimated Study Completion Date :||September 2020|
Active Comparator: Oxycodone Medication First
one hour before fMRI scan participants will be given a single dose 15mg immediate release oxycodone
Drug: Oxycodone Medication First
Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
Other Name: Oxycodone
Placebo Comparator: Placebo First
one hour before fMRI scan participants will be given a single dose placebo.
Drug: Placebo First
Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
Other Name: placebo
- Change in functional connectivity following oxycodone administration [ Time Frame: Change in functional connectivity from initial fMRI scan to follow-up MRI scan, up to 4 weeks. ]Functional connectivity is measured by functional magnetic resonance imagery (fMRI). Change in functional connectivity between placebo and oxycodone fMRI scans will be assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03612713
|Contact: Caitlin Sharp, BA||(203) email@example.com|
|United States, Connecticut|
|Magnetic Resonance Research Center at The Anlyan Center Yale School of Medicine||Recruiting|
|New Haven, Connecticut, United States, 06511|
|Principal Investigator: Sarah Yip, PhD|
|Principal Investigator:||Sarah Yip, PhD||Yale University|